EA201071250A1 - Композиции и методы для лечения рака молочной железы - Google Patents

Композиции и методы для лечения рака молочной железы

Info

Publication number
EA201071250A1
EA201071250A1 EA201071250A EA201071250A EA201071250A1 EA 201071250 A1 EA201071250 A1 EA 201071250A1 EA 201071250 A EA201071250 A EA 201071250A EA 201071250 A EA201071250 A EA 201071250A EA 201071250 A1 EA201071250 A1 EA 201071250A1
Authority
EA
Eurasian Patent Office
Prior art keywords
present
treatment
breast cancer
methods
compositions
Prior art date
Application number
EA201071250A
Other languages
English (en)
Other versions
EA019224B1 (ru
Inventor
Джозеф С. Подольски
Роналд Д. Виле
Original Assignee
Репрос Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40758440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201071250(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Репрос Терапьютикс Инк. filed Critical Репрос Терапьютикс Инк.
Publication of EA201071250A1 publication Critical patent/EA201071250A1/ru
Publication of EA019224B1 publication Critical patent/EA019224B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к области лечения рака. В частности, настоящее изобретение относится к лечению и/или предупреждению у пациентки рака молочной железы. Также раскрываются композиции для практического использования настоящих методов, включающие в себя селективные модуляторы рецепторов прогестерона, которые оказывают воздействие в качестве агонистов прогестерона на матку и в качестве антагонистов прогестерона в тканях молочной железы, а также демонстрируют только низкое сродство к рецепторам глюкокортикоида и эстрогена. Варианты настоящего изобретения также раскрывают методы по предупреждению развития рака молочной железы у пациенток, проходящих гормонозаместительную терапию или эстрогенотерапию.
EA201071250A 2008-04-28 2009-04-27 Композиции и методы для лечения рака молочной железы EA019224B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4845208P 2008-04-28 2008-04-28
PCT/US2009/041836 WO2009134723A1 (en) 2008-04-28 2009-04-27 Pregesteron antagonists such as cdb-4124 in the treatment of breast cancer

Publications (2)

Publication Number Publication Date
EA201071250A1 true EA201071250A1 (ru) 2011-04-29
EA019224B1 EA019224B1 (ru) 2014-02-28

Family

ID=40758440

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071250A EA019224B1 (ru) 2008-04-28 2009-04-27 Композиции и методы для лечения рака молочной железы

Country Status (22)

Country Link
US (2) US20110053900A1 (ru)
EP (2) EP2974772A1 (ru)
JP (1) JP5576362B2 (ru)
KR (1) KR101349737B1 (ru)
CN (1) CN102099040B (ru)
AR (1) AR071419A1 (ru)
AU (1) AU2009241360B2 (ru)
BR (1) BRPI0911112A2 (ru)
CA (1) CA2722637C (ru)
CL (1) CL2009001011A1 (ru)
EA (1) EA019224B1 (ru)
HK (1) HK1155084A1 (ru)
IL (2) IL208845A (ru)
ME (1) ME01122B (ru)
MX (1) MX2010011273A (ru)
MY (1) MY161549A (ru)
NI (1) NI201000184A (ru)
NZ (1) NZ589534A (ru)
TW (1) TWI539953B (ru)
UA (1) UA101192C2 (ru)
WO (1) WO2009134723A1 (ru)
ZA (1) ZA201007648B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2582713A1 (en) 2010-06-17 2013-04-24 MSD Oss B.V. (11 beta,17 alpha)-11-(4-(2-11c-acetyl)phenyl)-17,23-epoxy-19,24-dinorchola-4,9,20-trien-3-one
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
WO2013052652A1 (en) 2011-10-04 2013-04-11 Erard Gilles Methods and systems for identifying and treating anti-progestin sensitive tumors
FR2997628B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
CN109908355B (zh) * 2013-03-15 2022-11-15 阿普雷奇亚制药有限责任公司 包含左乙拉西坦的快速分散剂型
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
HU230381B1 (hu) * 2014-02-17 2016-03-29 Richter Gedeon Nyrt Ipari eljárás szteroid intermedier előállítására
CN113559075A (zh) 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
BR112018005999A2 (pt) 2015-09-25 2019-01-08 Context Biopharma Inc métodos para a produção de intermediários de onapristona
MX2018007154A (es) 2015-12-15 2019-01-10 Context Biopharma Inc Composiciones de onapristona amorfa y metodos para hacer las mismas.
TWI753892B (zh) 2016-03-28 2022-02-01 美商英塞特公司 作為ｔａｍ抑制劑之吡咯并三嗪化合物
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
WO2018106914A1 (en) * 2016-12-09 2018-06-14 Repros Therapeutics Inc. Oral pharmaceutical compositions comprising an unmicronized selective progesterone receptor as active agent
TWI832871B (zh) 2018-06-29 2024-02-21 美商英塞特公司 Axl/mer 抑制劑之調配物
RU2679625C1 (ru) * 2018-11-08 2019-02-12 Ильясов Шамиль Сионович ПРИМЕНЕНИЕ 3-О-СУЛЬФАМОИЛОКСИ-6-ОКСА-7β-МЕТИЛ-D-ГОМО-8α-ЭСТРА-1,3,5(10)-ТРИЕН-17а-ОНА ДЛЯ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ВКЛЮЧАЯ ТРИЖДЫ-НЕГАТИВНУЮ ФОРМУ, И СПОСОБ ЕГО ПОЛУЧЕНИЯ

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3347126A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3506785A1 (de) 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3625315A1 (de) 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
US5446178A (en) 1987-03-18 1995-08-29 Schering Aktiengesellschaft Process for preparing 19,11β-bridged steroids
ATE69820T1 (de) 1987-04-24 1991-12-15 Akzo Nv 11-arylestranderivate und 11-arylpregnanderivate.
DE3878198T2 (de) 1987-12-12 1993-06-24 Akzo Nv 11-arylsteroid-derivate.
DE3820948A1 (de) 1988-06-16 1989-12-21 Schering Ag 10ss, 11ss-ueberbrueckte steroide
DE3822770A1 (de) 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
DE3832303A1 (de) 1988-09-20 1990-04-12 Schering Ag 11ss-phenyl-14ssh-steroide
DE3917274A1 (de) 1989-05-24 1990-11-29 Schering Ag 9(alpha)-hydroxy-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3921059A1 (de) 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
DE4042007A1 (de) 1990-12-22 1992-06-25 Schering Ag 6,7-modifizierte-11(beta)-aryl-4-estrene
US5407928A (en) 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
DE4038128A1 (de) 1990-11-27 1992-06-04 Schering Ag 8-en-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
ZA929315B (en) 1991-12-20 1993-05-24 Akzo Nv 17-spirofuran-3'-ylidene steroids.
DE4216003A1 (de) 1992-05-12 1993-11-18 Schering Ag Dissoziierte kompetitive Progesteronantagonisten
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
DE4216004B4 (de) 1992-05-12 2008-03-27 Bayer Schering Pharma Akiengesellschaft Verwendung kompetitiver Progesteronantagonisten
DK0650480T3 (da) 1992-07-01 2002-05-13 Ortho Pharma Corp 1-Arylsulfonyl-3-phenyl-1,4,5,6-tetrahydropyridaziner
DE4332284C2 (de) 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4434488A1 (de) 1994-09-14 1996-03-21 Schering Ag Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5576310A (en) 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
US5696130A (en) 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Tricyclic steroid receptor modulator compounds and methods
AU714959B2 (en) * 1995-02-02 2000-01-13 Schering Aktiengesellschaft Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
DK0900234T3 (da) * 1996-05-01 2000-11-06 Us Gov Health & Human Serv 21-substituerede progesteronderivater anvendt som nye antigestagener
US5753655A (en) 1996-10-10 1998-05-19 Ortho Pharmaceutical Corporation 1-arylsulphonyl, arylcarbonyl and arylthiocarbonyl pyridazino derivatives and methods of preparation
DE19652408C2 (de) 1996-12-06 2002-04-18 Schering Ag Steroidester, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneimitteln
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
DE19809845A1 (de) 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
CA2403756C (en) * 2000-03-17 2010-02-09 Hyun K. Kim Structural modification of 19-norprogesterone i: 17-.alpha.-substituted, 11-.beta.-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
IN191020B (ru) * 2000-03-28 2003-09-13 Dabur Res Foundation
BR0114665A (pt) * 2000-10-18 2004-01-13 Schering Ag Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio
WO2007103510A2 (en) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
JP5379121B2 (ja) * 2007-04-05 2013-12-25 ユニバーシティ・オブ・カンザス プルランを含む速溶性医薬組成物
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案

Also Published As

Publication number Publication date
TW201002330A (en) 2010-01-16
CL2009001011A1 (es) 2009-09-25
BRPI0911112A2 (pt) 2015-10-06
ME01122B (me) 2013-03-20
EA019224B1 (ru) 2014-02-28
US20140343022A1 (en) 2014-11-20
IL247093A0 (en) 2016-09-29
AR071419A1 (es) 2010-06-16
JP2011518883A (ja) 2011-06-30
UA101192C2 (ru) 2013-03-11
KR101349737B1 (ko) 2014-02-07
CN102099040A (zh) 2011-06-15
CA2722637C (en) 2015-03-10
KR20110003553A (ko) 2011-01-12
WO2009134723A9 (en) 2010-01-21
HK1155084A1 (en) 2012-05-11
MX2010011273A (es) 2010-12-21
MY161549A (en) 2017-04-28
US20110053900A1 (en) 2011-03-03
EP2974772A1 (en) 2016-01-20
IL208845A0 (en) 2011-01-31
JP5576362B2 (ja) 2014-08-20
WO2009134723A1 (en) 2009-11-05
AU2009241360B2 (en) 2012-03-08
TWI539953B (zh) 2016-07-01
CA2722637A1 (en) 2009-11-05
ZA201007648B (en) 2011-07-27
NZ589534A (en) 2012-08-31
IL208845A (en) 2016-08-31
EP2293798A1 (en) 2011-03-16
NI201000184A (es) 2011-08-10
AU2009241360A1 (en) 2009-11-05
CN102099040B (zh) 2013-06-19

Similar Documents

Publication Publication Date Title
EA201071250A1 (ru) Композиции и методы для лечения рака молочной железы
EA201071249A1 (ru) Режимы дозирования антипрогестинов
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
EA200970409A1 (ru) Композиции и способы, предназначенные для подавления эндометриальной пролиферации
CU20120175A7 (es) Compuestos derivados de 6,7-dihidro-5h-benzo[7]anulenos
MX338290B (es) Tratamiento de enfermedad de alzheimer, perdida de cognición, perdida de memoria y demencia con precursores de esteroides sexuales en conbinación con moduladores selectivos del receptor de estrógenos.
EA200970835A1 (ru) Индазолы, применяемые для лечения расстройств, опосредуемых эстрогеновым рецептором бета
ATE514700T1 (de) Neues tetrazyklisches heteroatom mit als sexualsteroidhormon-rezeptormodulatoren geeigneten derivaten
MX2010010799A (es) Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
WO2010099003A3 (en) Compositions and methods for visualizing and eliminating cancer stem cells
EA201990106A1 (ru) Режим приема селективного модулятора рецептора прогестерона (sprm)
EA201491614A1 (ru) Способ лечения гинекологических заболеваний
EA201591793A1 (ru) Лактамные соединения в качестве селективных агонистов ep4-рецепторов для применения при лечении опосредованных ep4 заболеваний и состояний
TW200833710A (en) Treatment for spinal muscular atrophy
PA8771801A1 (es) Heterociclos sulfonilados utiles para la modulacion del receptor de progesterona
EA200970376A1 (ru) Peg-илированный паратиреоидный гормон в качестве модулятора рецептора паратиреоидного гормона и его применение
MA32477B1 (fr) Derives estratrienes comprenant des bioisosteres heterocycliques pour le cycle a phenolique
EA201000779A1 (ru) СОЕДИНЕНИЯ-АНАЛОГИ 6-ОКСА-8α-СТЕРОИДНЫХ ЭСТРОГЕНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ
EA201000097A1 (ru) 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов
UA98124C2 (ru) Применение антагониста прогестерона для лечения эндометриоза
RU2010130718A (ru) Способ гормональной терапии для ревитализации женщин

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU